CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+7.78%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.71B
AUM Growth
+$1.71B
(-2.4%)
Cap. Flow
+$34.6M
Cap. Flow
% of AUM
2.02%
Top 10 Holdings %
Top 10 Hldgs %
65.15%
Holding
68
New
6
Increased
13
Reduced
6
Closed
18
Top Buys
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$32.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$26.2M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$26.2M |
| 4 |
Immunovant
IMVT
|
$25.9M |
| 5 |
Structure Therapeutics
GPCR
|
$24.2M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$41.4M |
| 2 |
Design Therapeutics
DSGN
|
$32.4M |
| 3 |
89bio
ETNB
|
$25.6M |
| 4 |
Axsome Therapeutics
AXSM
|
$24.4M |
| 5 |
Viridian Therapeutics
VRDN
|
$20.2M |
Sector Composition
| 1 | Healthcare | 98.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $464M | 27.07% | 8,142,100 | – | – |
|
2
BridgeBio Pharma
BBIO
$9.89B
| $123M | 7.17% | 4,662,530 +493,351 | +12% | +$13M |
|
|
AMAM
3
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $114M | 6.66% | 9,923,689 +307,534 | +3% | +$3.54M |
|
4
Arcellx
ACLX
$3.85B
| $77.1M | 4.5% | 2,150,000 +150,000 | +8% | +$5.38M |
|
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $76.1M | 4.44% | 2,000,000 +690,000 | +53% | +$26.2M |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $57.4M | 3.35% | 3,850,000 +50,000 | +1% | +$746K |
|
7
Olema Pharmaceuticals
OLMA
$375M
| $55.6M | 3.25% | 4,504,764 +1,422,764 | +46% | +$17.6M |
|
|
8
Structure Therapeutics
GPCR
$1.11B
| $53.3M | 3.11% | 1,056,373 +480,000 | +83% | +$24.2M |
|
9
Biomea Fusion
BMEA
$116M
| $49.1M | 2.87% | 3,570,872 | – | – |
|
|
10
Immunovant
IMVT
$2.56B
| $47M | 2.74% | 1,225,000 +675,000 | +123% | +$25.9M |
|
11
Tarsus Pharmaceuticals
TARS
$2.47B
| $46.6M | 2.72% | 2,621,422 +1,200,000 | +84% | +$21.3M |
|
12
Cabaletta Bio
CABA
$133M
| $43.8M | 2.56% | 2,879,424 +657,685 | +30% | +$10M |
|
13
Vaxcyte
PCVX
$4B
| $33.9M | 1.98% | 665,000 | – | – |
|
|
14
Crinetics Pharmaceuticals
CRNX
$2.92B
| $32.8M | 1.91% | +1,101,904 | New | +$32.8M |
|
15
Immuneering
IMRX
$245M
| $32.3M | 1.88% | 4,204,364 | – | – |
|
16
Pharvaris
PHVS
$1.39B
| $28.4M | 1.66% | 1,361,460 +387,846 | +40% | +$8.09M |
|
|
RYZB
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $26.2M | 1.53% | +1,182,263 | New | +$26.2M |
|
18
EyePoint Pharmaceuticals
EYPT
$797M
| $25.6M | 1.49% | 3,200,000 | – | – |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $23.7M | 1.38% | 140,000 +60,000 | +75% | +$10.1M |
|
|
ALPN
20
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $21.8M | 1.27% | +1,900,000 | New | +$21.8M |
|
21
Erasca
ERAS
$445M
| $21.3M | 1.24% | 10,813,246 | – | – |
|
|
JBIO
22
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $21.2M | 1.24% | 1,561,696 | – | – |
|
|
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $21.1M | 1.23% | +2,625,000 | New | +$21.1M |
|
24
Rhythm Pharmaceuticals
RYTM
$6.85B
| $19.5M | 1.14% | 850,000 +250,000 | +42% | +$5.73M |
|
25
Edgewise Therapeutics
EWTX
$1.51B
| $16.9M | 0.99% | 2,946,887 | – | – |
|